Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 23 of the 37 sources its claims cite were checked for support.

Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection

Open access

Abstract

Gene augmentation therapy is a promising treatment for incurable, blinding inherited retinal diseases, and intravitreal delivery is being studied as a safe alternative to subretinal injections. Adeno-Associated Viruses (AAV) are commonly-used vectors for ocular gene augmentation therapy. Naturally occurring pre-operative exposure and infection with AAV could result in presence of neutralizing antibodies (NAB's) in patients' serum, and may affect the safety and efficacy of treatment. Our aim was to characterize the humoral response against AAV pre- and post-intravitreal delivery of AAV2.7m8 vectors in a naturally-occurring sheep model of CNGA3 achromatopsia. Serial serum neutralization assays were performed to screen sheep for pre-exiting anti-AAV2 NAB's, and to assess the effect of intravitreal AAV2.7m8 injection on post-operative NAB titers and intraocular inflammation in sheep. The effect of viral dose and transgene type were also assessed. Serological screening revealed pre-operative seropositivity in 21.4% of animals, with age being a risk factor for the presence of anti-AAV2 NAB's. NAB titers increased following intravitreal AAV administration in the majority of sheep. There was no significant difference in the degree of post-operative serum neutralization between pre-operatively seronegative sheep and those with pre-existing antibodies. However, only sheep with pre-existing antibodies presented with signs of post-operative inflammation. We conclude that pre-existing anti-AAV2 NAB's do not affect the level of post-operative NAB titers; however, they increase the risk of post-operative ocular inflammation. Our results could have implications for the management of AAV-mediated ocular gene therapies, a technology being increasingly studied and used in patients.

Overview

CoChat Summary

TL;DR

In a naturally occurring sheep model of CNGA3 achromatopsia, pre-existing anti-AAV2 neutralizing antibodies were found in 21.4% of screened sheep and increased with age. After intravitreal AAV2.7m8 injection, NAB titers rose in most sheep, but only pre-operatively seropositive sheep showed post-operative ocular inflammation.

Key findings

  • Among 70 screened sheep, 15 (21.4%) were pre-operatively seropositive for anti-AAV2 NABs; seropositivity was 55% (11/20) in sheep older than one year versus 8% (4/50) in younger sheep, with a 6.875 relative risk in older animals.
  • Following intravitreal AAV2.7m8 injection, NAB titers increased in 9/12 sheep; the seronegative group showed a significant post-operative increase at 12 weeks, but there was no significant difference in post-operative NAB titers between pre-operatively seronegative and seropositive sheep.
  • Only sheep with pre-existing anti-AAV2 antibodies presented with post-operative inflammatory signs; inflammation grading differed significantly between seropositive and seronegative groups at 7–10 days post-operatively (p = 0.032).
  • No correlation was found between total viral vector dose injected and the degree of serum neutralization at 12 weeks post-operatively.

Methods

  • Retrospective serological and clinical analysis of sheep from the Volcani Center experimental flock: 70 ewes (63 wild type, 7 day blind) were screened for pre-existing anti-AAV2 NABs, and 12 sheep underwent uni- or bilateral intravitreal injection of AAV2.7m8 with different promoters, transgenes, and doses (Table 1).
  • Serum neutralization assays used HEK293T cells and AAV2.7m8-CMV-luciferase; samples reducing luminescence below 50% were considered seropositive. Clinical ophthalmic examinations graded inflammatory findings on a 0–4 scale.
  • Statistical analysis used Shapiro-Wilk, Student’s t test, repeated measures ANOVA, and linear regression, with p < 0.05 considered significant.

Limitations

  • The paper states that sample size is a major limitation, including too few animals per transgene to assess transgene effects and unequal unilateral versus bilateral injections preventing analysis of number of eyes injected.
  • The paper states that NAB detection used a single AAV serotype, that cross-reactivity with other serotypes could affect results, and that seroprevalence depends on the assay and definition of seropositivity.
  • The paper states that most seropositive sheep received non-coding vectors, preventing correlation between serological response and gene expression; it also notes the study was retrospective and the investigator was not blinded to group allocation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41434-024-00495-5

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The degree of serum neutralization in sheep before, and 12 weeks after, IVT injection. NABs were tested by NAB serum neutralization assay. The graphs present the degree of luminescence (indicative of cellular transduction by AAV2) and its inhibition by NABs in serial dilutions of sheep serum. The values are shown as mean ± SE. Samples with no sheep serum were translated to 100% luminescence. Serum samples that reduced luminescence below 50% (dashed, horizontal line) were considered to have NABs. Two controls are depicted in each graph - a positive control of pooled serum from sheep who were previously exposed to AAV (gray), and a negative control of a seronegative sheep that did not undergo IVT injection (black). a Titers of anti-AAV2 NABs in seronegative (blue, n = 7) and seropositive (green, n = 5) sheep before IVT injection. b Change in the titers of anti-AAV2 NABs in seronegative sheep (n = 7), before (blue) and 12 weeks after IVT injection (dashed blue). c Change in the titers of anti-AAV2 NABs in seropositive sheep (n = 5), before (green) and 12 weeks after (dashed green) IVT injection. d Titers of anti-AAV2 NABs in seronegative (dashed blue, n = 7) and seropositive (dashed green, n = 5) sheep 12 weeks after IVT injection. Difference between pre- and post-operative samples (b, c) was tested using repeated measures ANOVA and difference between seropositive and seronegative sheep (panels a, d) was tested using Student’s t-test. *p < 0.05.
Fig. 1 The degree of serum neutralization in sheep before, and 12 weeks after, IVT injection. NABs were tested by NAB serum neutralization assay. The graphs present the degree of luminescence (indicative of cellular transduction by AAV2) and its inhibition by NABs in serial dilutions of sheep serum. The values are shown as mean ± SE. Samples with no sheep serum were translated to 100% luminescence. Serum samples that reduced luminescence below 50% (dashed, horizontal line) were considered to have NABs. Two controls are depicted in each graph - a positive control of pooled serum from sheep who were previously exposed to AAV (gray), and a negative control of a seronegative sheep that did not undergo IVT injection (black). a Titers of anti-AAV2 NABs in seronegative (blue, n = 7) and seropositive (green, n = 5) sheep before IVT injection. b Change in the titers of anti-AAV2 NABs in seronegative sheep (n = 7), before (blue) and 12 weeks after IVT injection (dashed blue). c Change in the titers of anti-AAV2 NABs in seropositive sheep (n = 5), before (green) and 12 weeks after (dashed green) IVT injection. d Titers of anti-AAV2 NABs in seronegative (dashed blue, n = 7) and seropositive (dashed green, n = 5) sheep 12 weeks after IVT injection. Difference between pre- and post-operative samples (b, c) was tested using repeated measures ANOVA and difference between seropositive and seronegative sheep (panels a, d) was tested using Student’s t-test. *p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 0 Not valid · 5 Not checked · 46 Own results and interpretations

39 more claims · 2 with their cited sources checked

Create a free account to see all 68 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

See all 3

Metadata

Authors
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R.
Affiliations
  • Agricultural Research Organization (IL)
  • Hebrew University of Jerusalem (IL)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Ofri, Ron
Venue
Gene Therapy
Published
2024-10-29
Volume
31
Issue
11-12
Pages
580-586
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
OpenAlex
W4403876117
Cited by
3
References
43
Citations by year
2026: 2 · 2025: 1
FWCI
0.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Gene Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Ministry of Health, State of Israel (3-0000-15068)
  • Israel Science Foundation (1257/15)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus type 2, neutralizing antibodies, intravitreal gene therapy, sheep model, humoral immune response, age as risk factor, viral dose
MeSH terms
Dependovirus, Animals, Antibodies, Viral, Genetic Vectors, Sheep, Genetic Therapy, Transgenes, Antibodies, Neutralizing, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection. https://app.cochat.ai/papers/10.1038/s41434-024-00495-5
The paper
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R. (2024). Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection. Gene Therapy. https://doi.org/10.1038/s41434-024-00495-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.